Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6180809 | 0.90 | MMP14 (0.57) | MMP14MMP13 | |
| SCHEMBL6202741 | 0.90 | MMP13 (0.47) | MMP14MMP13 | |
| SCHEMBL6183010 | 0.88 | MMP14 (0.50) | MMP14MMP13 | |
| SCHEMBL6181445 | 0.88 | MMP13 (0.45) | MMP14MMP13 | |
| SCHEMBL6199509 | 0.85 | MMP13 (0.48) | MMP14MMP13 | |
| SCHEMBL6183820 | 0.84 | MMP14 (0.48) | MMP14MMP13 | |
| SCHEMBL6181925 | 0.83 | MMP13 (0.46) | MMP14MMP13 | |
| SCHEMBL6183263 | 0.82 | MMP13 (0.57) | MMP14MMP13 | |
| SCHEMBL6182645 | 0.81 | MMP13 (0.47) | MMP14MMP13 | |
| SCHEMBL6181473 | 0.80 | MMP13 (0.44) | MMP14MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919332-B2 | N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030232849-A1 | N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003090751-A1 | PYRIMIDINE-2, 4, 6-TRIONE METALLO-PROTEINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232849-A1 | N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | MMP8, MMP9, MMP1 | MMP14 25/4885MMP13 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.